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Summary: The concentrations of proline, hydroxyproline, glycine and serine were determined in the plasma
of 39 haemodialysis patients and 18 healthy subjects, using liquid chromatography with fluorescence detection.
Plasma cpncentrations of the N-terminal immunoreactive parathyrin were also measured. In haemodialysis
patients, the plasma concentrations of glycine (p < 0.01), hydroxyproline (p < 0.05) and proline (p < 0.10)
were significantly increased, whereas the serine concentrations (p < 0.01) were decreased, compared with those
of the healthy controls. Haemodialysis patients showed greatly elevated plasma N-terminal immunoreactive
parathyrin valües (> 30 pmol/1), which showed a signiflcant correlation with the hydroxyproline values
(r = 0.79). Fourteen haemodialysis patients received erythropoietin therapy. In these patients, changes in the
concentrations öf plasma amino acids were observed up to one year after the beginning of therapy. In the
course of the erythroppietin therapy, the plasma cöücentrations of glycine (p < 0.05) and hydroxyproline
(p < 0.10) of the haemodialysis patients decreased, whereas the concentration of serine increased (p < 0.05)
to approximately normal values. The resülts indicate that erythropoietin therapy leads to a normalization of
amino acid metabolism.
Introduction
Osteodystrophies and elevated concentrations of hy-
droxyproline in plasma are closely correlated in pa-
tients with chrpnic renäl diseases. Hence, the concen-
tration of free hydroxyproline in plasma was recom-
J) Enzymes
Hydroxyproline oxidase (EC l'.4.3.—)
Glycine hydroxymethyltransferase
(Serine hydroxymethylase) (EC 2.1.2.1)
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mended äs a useful biochemical marker for diagnosis
and therapy of bone diseases (1). Varghese et al. (1)
showed that the ratio of free plasma hydroxyproline
to peptide-bound hydroxyproline was unchanged in
haemodialysis patients with and without visible bone
condition, and concluded that catabolism is not in-
hibited in haemodialysis patients. Hydroxyproline is
degraded in the liver to A^-hydroxy-pyrrolidine-S-
carboxylate by hydroxyproline oxidase1) (fig. 1). It has
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been shown experimentally (2) that hydroxyproline is
the main biosynthetic precursor of serine in the prox-
imal tubulus of the kidney. Glycine is an intermediate
in the degradation of hydroxyproline, and it also
serves s precursor of serine biosynthesis. Plasma
concentrations of serine are usually lowered in
uraemic patients (3, 4). A disturbance of serine bio-
synthesis might therefore be reflected by an elevated
concentration of plasma hydroxyproline, although
other pathways of glycine and serine must be taken


















Fig. 1. Pathway of hydroxyproline metabolism in serine bio-
synthesis (2).
Haemodialysis patients are normally anaemic. Some
metabolic disturbances in haemodialysis patients are
therefore closely related to their anaemia (5). This is
in part accounted for by the reduced erythropoietin
biosynthesis of the diseased kidney. The reduced os-
motic resistance of erythrocytes in cases of elevated
plasma concentrations of parathyrin might also con-
tribute to anaemia (6). Erythropoietin produced by
genetic engineering techniques can now be sed to
treat anaemia in haemodialysis patients. In the present
study, we have determined aspartate, glycine, proline,
hydroxyproline and serine in the plasma of haemo-
dialysis patients and healthy subjects, and we have
investigated the extent to which the disturbed metab-
olism of these mino acids in haemodialysis patients




Eighteen healthy subjects and 39 haemodialysis patients were
included in the study. Fourteen of the haemodialysis patients
were selected for erythropoietin therapy.
The control group included 6 male and 12 female persons from
21 to 56 years of age. The patient group included 15 men and
24 women from 21 to 76 years of age. Tne erythr poietin group
included 2 men and 12 women from 26 to 76 years of age, who
were suffering from nephronophthisis (n = 1), nephirosclerosis
(n = 2), analgesia nephropathy (n = 4), glomerulonephritis
(n = 3), nephrolithiasis with interstitial nephritis (n = 2) aiid
chronic pyelonephritis (n = 2). The patients were haemodia-
lysed 3 times a week for 4—5 hours over a period of 15 t 111
months. In the erythropoietin groupj the patients were injected
intravenously with 100 U erythropoietin per kg body weight
after each dialysis. When a h emoglobin concentration of 100
g/l was reached, the patients were maintained at this level by
individual dose reduction. Before and in course pf erythropoi-
etin therapy, all patients received phosphate lowering drugs if
necessary. In course of the study 6 patients interrupted the
therapy. With the consent of the patients, blood samples were
collected by vein puncture in heparinized Sarstedt safety mono-
vettes before dialysis. Recombinant human erythr poietin s




Blood samples were centrifuged for 10 minutes at 3000g, and
200 μΐ plasma portions were immediately lyophilized and stored
at -20°C.
Amino acid analysis
The following methods for amino acid analysis were pplied
(T)·
1. Reagents and equipment
Extraction buffer: 800 ml methanol H- 200 ml 50 mmol/1 sodium
acetate pH 7.0.
Borate buffer: 0.5 mol/1 pH 9.5.
Reagent I: 50 mg -phthaldialdehyde in 4.5 ml methanol, 500
μΐ borate buffer and 50 μΐ 2-mercaptpethanol.
Reagent ίί: 50 mg -phthaldialdehyde in 4.5 ml methanol and
500 μΐ borate buffer.
Eluent A: 220 ml methanol + 780 ml 50 mmol/1 sodium acetate
pH 7.0.
Eluent B: 750 ml methanol -i- 250 ml 50 mmol/1 sodium acetate
pH 7.0.
Reagent III: 50 mg 7-chloro-4-nitrobenz-2-oxa-1.3-diazole in
5 ml methanol.
The following HPLC equipment was used: Du Pont 850 System,
Kontron fluorescence detector SFM 23, Lichrospher RP 18
(5 μπα) column (25 cm, 4.6 mm id.).
2. Serine, glycine, aspartate detennination
Lyophilisates were extr cted with 1000 μΐ extraction buffer.
Extracts (500 μΐ) were mixed with 200 μΐ borate buffer, 50 μΐ
internal Standard (2 μg hofrioserine) and 100 μΐ reagent I. After
a reaction time of 10 minutes the reaction was stopped by
addition of 50 μΐ 0.1 mol/1 HC1. The reaction mixture (50 μΐ)
was diluted l: 5 with eluent A and 50 μΐ of this dilution were
injected onto the HPLC column. >
Elution gradient conditions: 20 minutes 10-^30% eluent B,
linear; 20 minutes 30—100% eluent B, linear; 5 minutes 100 —
10% eluent B, linear.
Detection: Excitation at 330 nm, emissi n at 450 nm.
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3. Proline, hydroxyproline determination
To the lyophilised plasma sample were added 500 μΐ extraction
buffer, followed by vortexing then centrifugation for l minute
at 3000 g. The extract (200 μΐ) was mixed wilh 100 μΐ borate
buffer, 25 μΐ internal Standard (2 μΐ 3.4-dehydroproline) and
50 μΐ reagent II and incubated for l minute at 60 °C. Reagent
III (50 μΐ) was added and the mixture was incubated for 5
minutes at 60 PC. After addition of 25 μΐ 2 mol/1 HC1 and l: 5
dilution with eluent A, 50 μΐ were injected onto the HPLC
column.
Elution gradient conditions: 15 minutes 10—50% eluent B,
exponent 2; 5 minutes 50-100% eluent B, linear.
Detection: Excitation at 470 nm, emission at 530 nm.
The direct extraction of lyophilisates results in recoveries of
amino acids up to nearly 100%. Coefficients of Variation for
determination were (in series and from day to day, n = 5):
serine 6.2%, 5.6%; glycine 7.0%, 8.2%; aspartate 4.6%, 8.6%;
proline 3.4%, 2.5%, and hydroxyproline 2.7%, 2.4%.
Haemoglobin assay
Haemoglobin was determined s haemiglobin cyanide (Mercko-
test 3317, Fa. Merck). l
Parathyrin assay
Parathyrin was measured using the Human N-Tact Parathyroid
Hormone-Radioimraunoassay Kit No 6900 by INC-Immuno
Nuclear (Fa. IBL, Hamburg). Intact parathyrin is present in
normal plasma at a concentration of ~ 5 pmol/1. Plasma also
contains biologically inactive fragments (mid-region-sequence
35—64 and C-region sequence 65 — 84) at a ratio to intact
parathyrin of 100:1. These inactive fragments cross-react with
most parathyrin radioimmunoassays (8). The N-Tact Para-
thyrid Hormone kit overcomes these obstacles by an extraction
and concentration procedure using speciflc adsorption particles,
which remove intact parathyrin and N-terminal-fragments. The
correlation between biologically active parathyrin and the val-'
ues determined with this kit is 95%.
Results
Haemodialysis patients showed elevated plasma con-
centrations f glycine, hydroxyproline and proline,
and significantly lowered serine values, compared with
the coiitrol group (tab. 1). Plasma concentrations of
hydroxyproline and parathyroid hormone (N-termi-
nal immunoreactive parathyrin) showed no or only
very poor correlation in haemodialysis patients:
y = 0.68 χ + 10.5 (r = 0.54) (y = hydroxyproline
concentration μπιοΐ/ΐ, χ = N-terminal immunoreac-
tive parathyrin concentration pmol/1). A correlation
between plasma concentrations of hydroxyproline and
N-terminal immunoreactive parathyrin was found,
however, in all patients (n = 16) showing highly ele-
vated plasma N-terminal immunoreactive parathyrin
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Fig. 2. Correlation of plasma concentrations of free hydroxy-
proline (Hyp) and parathyroid hormone (N-terminal
immunoreactive parathyrin, i-PTH) in haemodialysis
patients (n = 14)
= 1.15 CJ.PTH - 38.34 (r = 0.79).
The success of the erythropoietin therapy can be mon-
itored by the determination of blood haemoglobin
(tab. 2). The desired haemoglobin content of 100 g/l
was attained after approximately 12 weeks. In the 14
patients before erythropoietin therapy, plasma levels
of N-terminal immunoreactive parathyrin were 22.9
± 27.0 prnol/1. One year after the beginning of ther-
apy the levels of N-terminal immunoreactive para-
thyrin wefe 14.2 + 10.6 pmol/1. The plasma levels of
calcium, inorganic phosphate and alkaline phospha-
tase were slightly but not significantly increased dur-
irig the course of the erythropoietin therapy (tab. 3).
Tab. 1. Free concentrations of amino acids in the plasma of healthy subjects (controls) and haemodialysis patients. Significance
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Tab. 2. Haemoglobin plasma concentrations (g/l) in 14 hae-
modialysis patients in the course of erythropoietin ther-
apy before, 4 weeks and l year after beginning of the
therapy. Eighteen healthy subjects served s controls.
Significance of t values by Student** i index in reference













































Surprisingly, there is a significant increase in the
plasma concentration of serine, and a simultaneous,
significant drop in the glycine and hydroxyproline
concentrations during the correction of the anaemia
(tab. 4). The slightly elevated proline concentrations
observed in haemodialysis patients ret rn to normal
values after 12 weeks of erythropoietin therapy.
After one year of therapy the patient group was
reduced to 8 patients. In this group, proline increased
slightly and serine decreased slightly, compared with
the values at 12 weeks, whereas hydroxyproline con-
centf ations decreased further to a normal level (fig. 3).
Discussion
The occurrence of elevated glycine, hydroxyproline
and proline concentrations s well s lowered serine
concentrations in the plasma of patients with chronic
renal disease has been known for some time (1> 3, 4,
10). However, the age^dependent increase of plasma
levels of hydroxyproline should also be taken irito
Tab. 3. Concentrations of calcium, inorganic phosphate, parathyroid horm ne (N^terminal immunoreactive parathyrin), and












S. E. M. 0.04
8 Mean 2.41
S.D. 0.14




























Tab. 4. Concentrations of free amino acids in the plasma of 14 haemodialysis patients in the course of erythropoietin therapy
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ilil 1 year after
Fig. 3. Fraction of control (line 1.0, 18 healthy subjects) of plasma levels of amino acids in 14 haemodialysis patients in the
course of erythrppoietin therapy calculated äs follows: [(patients plasma amino acid level — control plasma amino acid
level) -4- control plasma amino acid level]. Significance oft values by Sludenfs t index p < 0.10 (*), p < 0.05 (**) related
to values before erythropoietin therapy.
consideration. The control group in our study had a
mean age of 42.4 +11.2 years, while the mean age
of the patient group receiving erythropoietin therapy
was 63.7 ± 13.4 years. Gilbertson et al. (11) have
proposed a procedure for calculating the age-depend-
ent normal plasma levels of total hydroxyproline (pro-
tein-bound + peptide-bound + free). In our study
we have so far measured only the free hydroxyproline
plasma levels. On the basis of the Gilbertson rule, for
a median age difference of 21.3 years we should cor^
rect the total hydroxyproline plasma levels by about
6%. The differences between control and patient
plasma levels of free hydroxyproline in our study were
in the ränge of 144 äs to 36% (fig. 3), i. e. far greater
than the age-dependent differences.
A comparison of the plasma cpneentrations of hy-
droxyproline with those of parathyrin showed initially
no correlation in the haemodialysis patients. How-
ever, the higher the parathyrin values, the more
strongly they were corfelated (fig. 2). According to
Varghese et al. (1), elevated hydroxyproline values
also occur without evidence of osteodystrophies. We
found strongly elevated hydroxyproline values (> 30
/ ) without excessively elevated parathyrin values
(< 10 pmol/1) in 6 (out of 39) haemodialysis patients,
but not one case of low or normal hydroxyproline
values with parathyrin values > 30 pmol/1.
Elevated hydroxyproline concentrations in plasma ap-
pear to be the result of metäbolic disturbances äs well
äs the marker symptom of osteodystrophies. In ad-
dition, in patients suffering from renal failure, the
impaired tubular reabsorption of amino acids must
be considered. The unexpected drop in glycine, hy-
droxyproline and proline concentrations and the in-
crease in serine concentrations towards a normaliza-
tion of the amino acid level in course of the eryth-
ropoietin therapy suggests a correction of amino acid
metabolism, including hydroxyproline. In the early
phase of therapy (first 12 weeks), the decrease of
plasma hydroxyproline concentrations showed a scat-
ter (for Standard deviations, see tab. 4). After one
year of therapy this scatter vanished, and the differ-
ences became significant.
Serine is mainly produced in liver and kidney from
the pfecursor glycine, involving the enzyme serine
hydroxymethylase1) and the cofactor tetrahydrofolic
acid (2). During the depletion of the glycine pool,
there is a simultaneous degradation of plasma hy-
droxyproline to produce more glycine. In an inter-
mediate Step, transamination between 4-hydroxy-L-
glutamate and oxalacetate produces 4-hydroxy-2-oxo-
glutarate and aspartate.
In the course of the erythropoietin therapy, the plasma
concentrations of aspartate increase (p < 0.01). It is
possible, however, that less hydroxyproline is pro-
duced during erythropoietin therapy, so that the re-
duction in hydroxyproline might indicate an improve-
ment in the osteodystrophic Situation (see Varghese
J. Clin. Chem. Clin. Biochem. / Vol. 27,1989 / No. fl
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et al. (1)). Further evidence for this assumption seems
to be the significant increase in the ratio, proline/
hydroxyproline, during the therapy. Measurements of
calcium, inorganic phosphate and alkaline phospha-
tase showed no significant changes during erythropie-
tin therapy. However, all patients received continu-
ously phosphate lowering drugs, which influence these
analytes. Hence this question cannot been settled on
the basis of the plasma concentrations alone, but
requires detailed biochemical investigations.
Doubtless the plasma concentrations of amino acids
in haemodialysis patients during erythropoietin ther-
apy might be influenced by dietary habits (4). The
patients were informed about the necessity to elimi-
nate such potential influences, and blood samples
were taken in the morning after overnight fasting.
Nevertheless, in normal adult subjects who underwent
starvation, the plasma concentrations of aspartate
(—40%) and proline (—23%) were diminished, while
those of glycine (+44%) and serine (+9%) were
elevated (12)": In our haemodialysis patients, the
plasma concentrations of aspartate (+169%), proline
(+31%) and glycine (+62%) were elevated, while
that of serine (—29%) was decreased. These values
agree with reports of Chami et al. (3), Young et al.
(4), Druml et al. (14) and others. We shoiild expect
an increase in the plasma levels of aspartate and
proline and a decrease of glycine and serine äs positive
nutritional effects. However, in our patients we see
during the erythropoietin therapy an increase in as-
partate, but a decrease in prolinefand glycme, and an
increase in serine, although after one year of therapy
the trend towards the normalization of proline and
serine is slightly reversed (fig. 3), Hence the measured
effects on amino acid metabolism in the coürse of
erythropoietin therapy were orily partly explained by
better nutrition. Without any doubt, however, deter-
minations of amino acid plasma concentrations,
which have been greatly facilitated and irnproved by
the newly developed high pressure liquid Chromato-
graphie fluorescence technique, will be of considerable
help in monitoring the coürse of the disease and the
therapy of haemodialysis patients.
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